Illumina, Inc. (ILMN)
| Market Cap | 32.26B +110.8% |
| Revenue (ttm) | 4.49B +4.9% |
| Net Income | 824.00M -34.4% |
| EPS | 5.37 -32.1% |
| Shares Out | 151.00M |
| PE Ratio | 39.78 |
| Forward PE | 37.45 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,017,764 |
| Open | 213.74 |
| Previous Close | 215.59 |
| Day's Range | 208.98 - 214.90 |
| 52-Week Range | 88.00 - 231.81 |
| Beta | 1.47 |
| Analysts | Buy |
| Price Target | 198.89 (-6.9%) |
| Earnings Date | Jul 30, 2026 |
About ILMN
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for ILMN stock is "Buy." The 12-month stock price target is $198.89, which is a decrease of -6.90% from the latest price.
News
Illumina management to meet with Piper Sandler
Meeting to be held on August 27 hosted by Piper Sandler.
Illumina management to meet virtually with Piper Sandler
Virtual Meeting to be held to be held on August 25-26 hosted by Piper Sandler.
Illumina downgraded to Hold from Buy at Freedom Broker
Freedom Broker downgraded Illumina (ILMN) to Hold from Buy with a price target of $185, up from $155. The firm says the company’s “strong quarter reinforces Illumina’s accelerating fundamental growth…
Illumina price target raised to $225 from $200 at Piper Sandler
Piper Sandler raised the firm’s price target on Illumina (ILMN) to $225 from $200 and keeps an Overweight rating on the shares following quarterly results. The firm cites another strong…
Illumina price target raised to $205 from $190 at Canaccord
Canaccord raised the firm’s price target on Illumina (ILMN) to $205 from $190 and keeps a Hold rating on the shares. The firm said the company’s Q2 performance was driven…
Illumina price target raised to $113 from $95 at Citi
Citi raised the firm’s price target on Illumina (ILMN) to $113 from $95 and keeps a Sell rating on the shares.
Illumina price target raised to $230 from $170 at RBC Capital
RBC Capital raised the firm’s price target on Illumina (ILMN) to $230 from $170 and keeps an Outperform rating on the shares. The company’s Q2 results are balancing somewhat stronger-than-expected…
Illumina price target raised to $210 from $192 at TD Cowen
TD Cowen raised the firm’s price target on Illumina (ILMN) to $210 from $192 and keeps a Hold rating on the shares. The firm said Q2 results were solid and…
Illumina price target raised to $140 from $120 at BofA
BofA raised the firm’s price target on Illumina (ILMN) to $140 from $120 and keeps an Underperform rating on the shares.
Illumina price target raised to $215 from $185 at Bernstein
Bernstein raised the firm’s price target on Illumina (ILMN) to $215 from $185 and keeps a Market Perform rating on the shares following quarterly results. The firm comes out of…
Illumina price target raised to $225 from $155 at Stifel
Stifel raised the firm’s price target on Illumina (ILMN) to $225 from $155 and keeps a Buy rating on the shares.
Illumina price target raised to $230 from $220 at JPMorgan
JPMorgan analyst Casey Woodring raised the firm’s price target on Illumina (ILMN) to $230 from $220 and keeps an Overweight rating on the shares. The firm says the company’s Q2…
Illumina price target raised to $226 from $200 at Guggenheim
Guggenheim raised the firm’s price target on Illumina (ILMN) to $226 from $200 and keeps a Buy rating on the shares. After the company beat consensus revenue and adjusted EPS…
Illumina price target raised to $160 from $145 at Barclays
Barclays raised the firm’s price target on Illumina (ILMN) to $160 from $145 and keeps an Underweight rating on the shares. The company’s NSX placements is set to moderate in…
Illumina Earnings Call Transcript: Q2 2026
Q2 2026 saw robust revenue and EPS growth, driven by strong clinical demand, expanding NovaSeq X placements, and innovation in multi-omics and AI-enabled offerings. Full-year guidance was raised for revenue and EPS, with clinical markets and new products expected to drive future growth.
Illumina Earnings release: Q2 2026
Illumina released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Illumina Slides: Q2 2026
Illumina has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Illumina Quarterly report: Q2 2026
Illumina has published its Q2 2026 quarterly earnings report on July 30, 2026.
Illumina reports Q2 adjusted EPS $1.31, consensus $1.23
Reports Q2 revenue $1.16B, consensus $1.13B. “Illumina (ILMN) delivered strong results during the second quarter. Momentum continued to build through the first half of 2026, as our technology is enabl...
Illumina raises FY26 adjusted EPS view to $5.30-$5.40 from $5.15-$5.30
FY26 consensus $5.23. Raises FY26 revenue view to $4.6B-$4.64B from $4.52B-$4.62B, consensus $4.57B. ROW organic revenue growth greater than 5%, versus prior guidance of 2%-4%.
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026
SAN DIEGO, July 30, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the second quarter of fiscal year 2026. Second quarter 20...
Fishbone Advisors Survey: Institutional Investors See Healthcare's AI Story as Overblown
CHICAGO--(BUSINESS WIRE)---- $ILMN #AI--Fishbone Advisors, a capital markets intelligence firm, today released a new report showing that healthcare's AI narrative has a credibility problem with instit...
Illumina price target raised to $210 from $175 at Leerink
Leerink analyst Puneet Souda raised the firm’s price target on Illumina (ILMN) to $210 from $175 and keeps an Outperform rating on the shares. The firm cites higher industry multiples.
Illumina adds three new member companies to Billion Cell Atlas alliance
Illumina (ILMN) announced that the Billion Cell Atlas alliance has added three new member companies, including AI-native drug developer Formation Bio. “As leaders in AI-driven drug discovery, design, ...
Illumina expands Billion Cell Atlas program with new AI drug developers
Partners will use unprecedented data scale to advance more precise medicines to approval SAN DIEGO, July 16, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that the Billion Cell At...